A 68-year-old man is evaluated in the intensive care unit for new-onset swelling of his ri… — USMLE Step 3

A $68$ -year-old man is evaluated in the intensive care unit for new-onset swelling of his right leg. He is currently on hospital day $8$ following a mitral valve replacement and has been receiving subcutaneous unfractionated heparin for deep vein thrombosis prophylaxis. On admission, his baseline platelet count was $240,000/\text{mm}^3$ ; today, it is $90,000/\text{mm}^3$ . A lower extremity venous duplex ultrasound reveals an acute deep vein thrombosis in the right femoral vein. Heparin-induced thrombocytopenia is suspected. All heparin-containing products are immediately discontinued, a continuous intravenous infusion of argatroban is initiated, and a serotonin release assay is sent.

Three days later, the patient's leg swelling has improved. His platelet count has increased to $165,000/\text{mm}^3$ , and his activated partial thromboplastin time has remained consistently in the therapeutic range. The serotonin release assay returns positive. The patient is clinically stable, and the critical care team plans to transition him to oral warfarin for long-term anticoagulation.

Which of the following is the most appropriate next step in the monitoring and treatment evaluation of this patient's anticoagulation?

A
Initiate warfarin, continue the argatroban infusion, and discontinue argatroban once the international normalized ratio is between $2.0$ and $3.0$
Initiate warfarin, continue the argatroban infusion, and discontinue argatroban once the international normalized ratio exceeds $4.0$ Cevap
C
Discontinue the argatroban infusion and initiate warfarin monotherapy with daily international normalized ratio monitoring
D
Discontinue the argatroban infusion, initiate therapeutic enoxaparin, and overlap with warfarin until the international normalized ratio is between $2.0$ and $3.0$
E
Continue argatroban monotherapy and delay the initiation of warfarin until the serotonin release assay is negative

Cevap

The correct answer is to initiate warfarin, continue the argatroban infusion, and discontinue argatroban once the international normalized ratio exceeds

4.0

In the management of heparin-induced thrombocytopenia (HIT), transition to oral warfarin should begin only after the patient is stable and the platelet count has recovered to at least

150,000/\text{mm}^3

. Because argatroban is a direct thrombin inhibitor, it falsely elevates the prothrombin time (PT) and the corresponding INR. When co-administered with warfarin, the two drugs have a synergistic effect on the INR value. To ensure that the patient is fully and therapeutically anticoagulated on warfarin alone once the parenteral agent is removed, hematology guidelines recommend overlapping the medications until the combined INR is greater than

4.0

. Once this threshold is achieved, argatroban is paused or discontinued, and a true warfarin-only INR is checked

4

6

hours later to confirm it has remained in the target therapeutic range of

2.0

3.0

Adım Adım Çözüm

Evaluate clinical stability and platelet recovery

The patient is clinically stable and platelets have recovered to

165,000/\text{mm}^3

Transitioning to warfarin in heparin-induced thrombocytopenia is unsafe until the platelet count reaches

\geq 150,000/\text{mm}^3

due to the risk of venous limb gangrene.

Determine the required pharmacological transition protocol

Warfarin must be overlapped with the direct thrombin inhibitor (argatroban).

An overlapping non-heparin parenteral anticoagulant prevents the transient hypercoagulable state caused by warfarin's rapid depletion of Protein C.

Identify the target laboratory parameter for safe discontinuation of the infusion

Argatroban should be discontinued only when the combined INR exceeds

4.0

Argatroban artificially prolongs the INR. A combined INR

> 4.0

provides confidence that once the infusion is stopped, the true, underlying warfarin-only INR will fall into the standard therapeutic range of

2.0

3.0

Anahtar Kavram

Patients with heparin-induced thrombocytopenia transitioning from argatroban to warfarin must overlap therapy until the combined INR is

> 4.0

due to argatroban's artificial prolongation of the prothrombin time.

Tahmini Süre:2m 0s

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru